| Bioactivity | Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity[1]. |
| Invitro | Ligufalimab 结合人 CD47 抗原，EC50 值为 0.078 nM，KD 值为 0.152 nM[1]。Ligufalimab (0-3000 nM) 不诱导红细胞血凝[1]。Ligufalimab (0.1、1、10 µg/mL) 以剂量依赖性方式诱导 Raji、Jurkat 和 Ramos 细胞的吞噬作用[1]。 |
| In Vivo | Ligufalimab(0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model) 抑制小鼠肿瘤生长[1]。 Animal Model: |
| Name | Ligufalimab |
| CAS | 2428381-55-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022 Nov;10(11):e005517. |